GRAFT VERSUS HOST DISEASE (GVHD)
Clinical trials for GRAFT VERSUS HOST DISEASE (GVHD) explained in plain language.
Never miss a new study
Get alerted when new GRAFT VERSUS HOST DISEASE (GVHD) trials appear
Sign up with your email to follow new studies for GRAFT VERSUS HOST DISEASE (GVHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis phase 3 trial compares two drug combinations given after a stem cell transplant to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The study will enroll 572 adults with blood cancers like leukemia or myelodysplasi…
Matched conditions: GRAFT VERSUS HOST DISEASE (GVHD)
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis study tests whether adding a new oral drug (ivarmacitinib) to standard medicines can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant from a female donor who has given birth. About 82 adults with blood cancers will receive t…
Matched conditions: GRAFT VERSUS HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Lower-Dose drug may make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis study tests whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. GVHD is a serious complication where donor cells attack the patient's body. The trial will enroll 41 adults and give the…
Matched conditions: GRAFT VERSUS HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a lower drug dose improve life after stem cell transplant for older adults?
Disease control Recruiting nowThis study is for adults aged 60 and older with blood cancers who need a stem cell transplant. It compares a standard high dose of a drug (cyclophosphamide) with a lower dose, both combined with another drug (sirolimus), to prevent graft-versus-host disease (GVHD). The goal is to…
Matched conditions: GRAFT VERSUS HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC